Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons resulting in progressive paralysis and respiratory failure. About 1 in every 400 people dies of ALS, usually within 3 to 5 years of symptom onset. The lack of effective therapy means that although the incidence is comparable to that of multiple sclerosis, the prevalence is low. The causes of ALS are largely unknown, but the only disease-modifying therapy, riluzole, was designed based on one hypothesis of disease causation, the excitotoxic hypothesis. In this paper we will review current ideas about the causes of ALS and the therapeutic opportunities they suggest.
CNS & Neurological Disorders - Drug Targets
Title: Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis
Volume: 7 Issue: 1
Author(s): Ammar Al-Chalabi and Vineeta B. Tripathi
Affiliation:
Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons resulting in progressive paralysis and respiratory failure. About 1 in every 400 people dies of ALS, usually within 3 to 5 years of symptom onset. The lack of effective therapy means that although the incidence is comparable to that of multiple sclerosis, the prevalence is low. The causes of ALS are largely unknown, but the only disease-modifying therapy, riluzole, was designed based on one hypothesis of disease causation, the excitotoxic hypothesis. In this paper we will review current ideas about the causes of ALS and the therapeutic opportunities they suggest.
Export Options
About this article
Cite this article as:
Al-Chalabi Ammar and Tripathi B. Vineeta, Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885110
DOI https://dx.doi.org/10.2174/187152708783885110 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Amyloid β-Peptide: The Inside Story
Current Alzheimer Research Somatostatin and Cognitive Function in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Animal Models for Neurodegenerative Diseases Associated to Accumulation of Misfolded Protein Aggregates (Executive Guest Editor: Claudio Soto)]
Current Pharmaceutical Design Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Selenium and Clinical Trials: New Therapeutic Evidence for Multiple Diseases
Current Medicinal Chemistry Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Biosynthesis of Flavin Cofactors in Man: Implications in Health and Disease
Current Pharmaceutical Design Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research The Chaperone-like Activity of Rat HspB8/Hsp22 and Dynamic Molecular Transition Related to Oligomeric Architectures In Vitro
Protein & Peptide Letters Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology